Benzinga | May 5, 2021 08:34AM EDT

NLS Pharma Reports Patent Issued In Europe For Its Mazindol Controlled-Release Formulation

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that the European Patent Office has granted the Company Patent No. EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD). The patent provides intellectual property protection for oral formulations containing immediate-release and sustained-release layers of mazindol for use in treating attention deficit disorders (ADD or ADHD), related deficit of alertness or decline of vigilance, or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.



"We are pleased to have obtained patent coverage in Europe covering our controlled-release formulation of mazindol as we advance the development of Quilience(r) (mazindol CR) to treat narcolepsy and potentially other sleep-wake disorders," said Alex Zwyer, Chief Executive Officer of NLS. "Earlier this year, we were granted a similar patent in Canada, and our U.S. patent application is pending review. Additionally, this newly issued patent augments the Orphan Drug Designations that we have for Quilience in both Europe and the U.S. Most patients with narcolepsy remain unsatisfied with current treatment options, and we believe that Quilience has potential to fill a major need in the market given mazindol's long history of safety and evidence of effectiveness in treating the symptoms of narcolepsy. We remain on track to initiate our prospective Phase 2 clinical study for Quilience this summer as we focus on bringing this treatment option to patients suffering from narcolepsy as soon as possible."